Ignite Creation Date:
2025-12-24 @ 9:21 PM
Ignite Modification Date:
2025-12-28 @ 2:08 AM
Study NCT ID:
NCT06114004
Status:
RECRUITING
Last Update Posted:
2025-06-25
First Post:
2023-10-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
Sponsor:
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SELNET-7-1
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None